Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Other Non-Current Assets (2016 - 2025)

Historic Other Non-Current Assets for Arcadia Biosciences (RKDA) over the last 12 years, with Q3 2025 value amounting to $148000.0.

  • Arcadia Biosciences' Other Non-Current Assets fell 975.61% to $148000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $148000.0, marking a year-over-year decrease of 975.61%. This contributed to the annual value of $96000.0 for FY2024, which is 9723.5% down from last year.
  • Arcadia Biosciences' Other Non-Current Assets amounted to $148000.0 in Q3 2025, which was down 975.61% from $148000.0 recorded in Q2 2025.
  • Arcadia Biosciences' Other Non-Current Assets' 5-year high stood at $3.5 million during Q4 2023, with a 5-year trough of $23000.0 in Q1 2021.
  • Moreover, its 5-year median value for Other Non-Current Assets was $165000.0 (2022), whereas its average is $337105.3.
  • In the last 5 years, Arcadia Biosciences' Other Non-Current Assets soared by 95212.12% in 2023 and then tumbled by 9723.5% in 2024.
  • Quarter analysis of 5 years shows Arcadia Biosciences' Other Non-Current Assets stood at $180000.0 in 2021, then skyrocketed by 83.33% to $330000.0 in 2022, then skyrocketed by 952.12% to $3.5 million in 2023, then tumbled by 97.24% to $96000.0 in 2024, then skyrocketed by 54.17% to $148000.0 in 2025.
  • Its last three reported values are $148000.0 in Q3 2025, $148000.0 for Q2 2025, and $96000.0 during Q1 2025.